Fuxing Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fuxing Li has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
En Wei
Nanchang University
1 shared publicationFei Zhao
Nanchang University
1 shared publicationGanyue Fu
Department of Neurological Intensive Care Unit, The Second Affiliated Hospital, Jiangxi Medical College, NanchangUniversity, Nanchang, China
1 shared publicationJianning Xu
Department of Intensive Care Unit, The Second Affiliated Hospital Jiangxi Medical College, NanchangUniversity, Nanchang, China
1 shared publicationMeng Wang
Department of Intensive Care Unit, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi, China
1 shared publicationRui Zhou
Department of Neurological Intensive Care Unit, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, Jiangxi, China
1 shared publication
Latest Publications
- Open Access
- 17 December 2025
- Published by Springer Nature in Research Square
The Lactate/Hematocrit Ratio and Prognosis in ICU Patients with Acute Myocardial Infarction: A Retrospective Cohort Study
Objective To assess the association between the lactate to hematocrit ratio (LHR) at ICU admission and all cause mortality at 28-day and 360-day in patients with acute myocardial infarction (AMI) and to test its added value beyond established severity scores. Methods This retrospective study used data from the Medical Information Mart for Intensive Care IV database (MIMIC IV, version 3. 1). Adult ICU patients with AMI were included. We applied multivariable Cox regression, receiver operating characteristic (ROC) analysis, Kaplan-Meier curves, subgroup analyses, and sensitivity analyses to examine the relation between admission LHR and 28-day and 360-day mortality. Results A total of 2884 patients were included. Compared with Q1, patients in Q4 had higher mortality risk at 28-days (hazard ratio [HR] 1. 799, 95% confidence interval [CI] 1. 304 to 2. 481, P < 0. 001) and at 360-days (HR 1. 520, 95% CI 1. 152 to 2. 006, P = 0. 003). The area under the ROC curve (AUC) for LHR was 0. 802 for 28-day mortality and 0. 796 for 360-day mortality. Adding LHR to existing scores improved model discrimination and reclassification as shown by the integrated discrimination improvement (IDI) and the net reclassification improvement (NRI). Restricted cubic spline (RCS) analysis showed an almost linear dose response relation between LHR and mortality. Findings were consistent in the complete case analysis. Conclusion LHR is an independent risk factor for short term and long term mortality in ICU patients with AMI. Adding LHR to current models improves prediction and may help identify high risk patients. Trial registration: Not applicable.
- 17 December 2025
- Published by Springer Nature in Research Square
Open AccessThe Lactate/Hematocrit Ratio and Prognosis in ICU Patients with Acute Myocardial Infarction: A Retrospective Cohort Study
Objective To assess the association between the lactate to hematocrit ratio (LHR) at ICU admission and all cause mortality at 28-day and 360-day in patients with acute myocardial infarction (AMI) and to test its added value beyond established severity scores. Methods This retrospective study used data from the Medical Information Mart for Intensive Care IV database (MIMIC IV, version 3. 1). Adult ICU patients with AMI were included. We applied multivariable Cox regression, receiver operating characteristic (ROC) analysis, Kaplan-Meier curves, subgroup analyses, and sensitivity analyses to examine the relation between admission LHR and 28-day and 360-day mortality. Results A total of 2884 patients were included. Compared with Q1, patients in Q4 had higher mortality risk at 28-days (hazard ratio [HR] 1. 799, 95% confidence interval [CI] 1. 304 to 2. 481, P < 0. 001) and at 360-days (HR 1. 520, 95% CI 1. 152 to 2. 006, P = 0. 003). The area under the ROC curve (AUC) for LHR was 0. 802 for 28-day mortality and 0. 796 for 360-day mortality. Adding LHR to existing scores improved model discrimination and reclassification as shown by the integrated discrimination improvement (IDI) and the net reclassification improvement (NRI). Restricted cubic spline (RCS) analysis showed an almost linear dose response relation between LHR and mortality. Findings were consistent in the complete case analysis. Conclusion LHR is an independent risk factor for short term and long term mortality in ICU patients with AMI. Adding LHR to current models improves prediction and may help identify high risk patients. Trial registration: Not applicable.
- 19 November 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 72
Cordycepin Mitigates Sepsis-Associated Encephalopathy by Promoting Microglial M2 Polarization via the IL-17a/IL-17RA/NF-κB Axis
Sepsis-associated encephalopathy (SAE) is a serious neurological complication of systemic infection, marked by cognitive deficits, neuroinflammation, and increased mortality. Microglial activation and proinflammatory signaling pathways, particularly involving IL-17a and NF-κB, are key contributors to SAE pathogenesis. Cordycepin (3′-deoxyadenosine), a bioactive nucleoside analog from Cordyceps militaris, exhibits potent anti-inflammatory and immunomodulatory effects, yet its role in SAE remains largely unexplored. In this study, a cecal ligation and puncture (CLP) mouse model was used to evaluate the neuroprotective effects of cordycepin. Behavioral tests showed that cordycepin significantly improved cognitive performance in septic mice. 16S rRNA sequencing showed that cordycepin restored gut microbial diversity disrupted by sepsis. Immunofluorescence analysis demonstrated preserved hippocampal neuronal integrity and attenuated neuroinflammation following treatment. Mechanistically, cordycepin suppressed peripheral Th17 cell expansion, reduced IL-17a levels in both circulation and brain tissue, and downregulated IL-17RA/NF-κB signaling in hippocampal microglia. Furthermore, it promoted polarization of microglia toward the anti-inflammatory M2 phenotype. Collectively, these findings suggest that cordycepin alleviates SAE by modulating the gut–immune–brain axis, suppressing IL-17a/IL-17RA/NF-κB signaling, and enhancing microglial M2 polarization, thereby offering a promising therapeutic strategy for sepsis-related cognitive impairment. Graphical Abstract
- 19 November 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 72
Cordycepin Mitigates Sepsis-Associated Encephalopathy by Promoting Microglial M2 Polarization via the IL-17a/IL-17RA/NF-κB Axis
Sepsis-associated encephalopathy (SAE) is a serious neurological complication of systemic infection, marked by cognitive deficits, neuroinflammation, and increased mortality. Microglial activation and proinflammatory signaling pathways, particularly involving IL-17a and NF-κB, are key contributors to SAE pathogenesis. Cordycepin (3′-deoxyadenosine), a bioactive nucleoside analog from Cordyceps militaris, exhibits potent anti-inflammatory and immunomodulatory effects, yet its role in SAE remains largely unexplored. In this study, a cecal ligation and puncture (CLP) mouse model was used to evaluate the neuroprotective effects of cordycepin. Behavioral tests showed that cordycepin significantly improved cognitive performance in septic mice. 16S rRNA sequencing showed that cordycepin restored gut microbial diversity disrupted by sepsis. Immunofluorescence analysis demonstrated preserved hippocampal neuronal integrity and attenuated neuroinflammation following treatment. Mechanistically, cordycepin suppressed peripheral Th17 cell expansion, reduced IL-17a levels in both circulation and brain tissue, and downregulated IL-17RA/NF-κB signaling in hippocampal microglia. Furthermore, it promoted polarization of microglia toward the anti-inflammatory M2 phenotype. Collectively, these findings suggest that cordycepin alleviates SAE by modulating the gut–immune–brain axis, suppressing IL-17a/IL-17RA/NF-κB signaling, and enhancing microglial M2 polarization, thereby offering a promising therapeutic strategy for sepsis-related cognitive impairment. Graphical Abstract
- Open Access
- 16 December 2023
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 37, 101608
Targeting STAT6 to mitigate sepsis-induced muscle atrophy and weakness: Modulation of mitochondrial dysfunction, ferroptosis, and CHI3L1-Mediated satellite cell loss
- 16 December 2023
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 37, 101608
Open AccessTargeting STAT6 to mitigate sepsis-induced muscle atrophy and weakness: Modulation of mitochondrial dysfunction, ferroptosis, and CHI3L1-Mediated satellite cell loss